What Happened?
Farmingdale, NY-based Codagenix Appointed Robert Coleman as Chief Executive Officer
About the Company
Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.
About the Person
Robert Coleman is Chief Executive Officer at Codagenix. Previously, Robert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile